Search Results
Feb 19, 2026, 07:00 ET Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update
Securities—BRIDGEWATER, N.J., Feb. 19, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Feb 13, 2026, 07:00 ET Insmed To Present at March 2026 Investor Conferences
BRIDGEWATER, N.J., Feb. 13, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Feb 05, 2026, 07:00 ET Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026
BRIDGEWATER, N.J., Feb. 5, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Jan 28, 2026, 07:00 ET Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress
Models—BRIDGEWATER, N.J., Jan. 28, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Jan 22, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jan 15, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jan 09, 2026, 07:00 ET Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
2026—BRIDGEWATER, N.J., Jan. 9, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Jan 08, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jan 02, 2026, 07:00 ET Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference
BRIDGEWATER, N.J., Jan. 2, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Jan 01, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated ("Insmed" or the "Company") (NASDAQ: INSM). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Dec 04, 2025, 07:00 ET Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Dec. 4, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Nov 18, 2025, 11:06 ET European Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
Health — BRIDGEWATER, N.J., Nov. 18, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver therapies to transform the lives of patients facing serious diseases, today announced
More news about: Insmed Incorporated
Nov 18, 2025, 11:00 ET European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
BRIDGEWATER, N.J., Nov. 18, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Nov 13, 2025, 07:00 ET Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good
BRIDGEWATER, N.J., Nov. 13, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Nov 05, 2025, 07:00 ET Insmed To Present at November and December 2025 Investor Conferences
BRIDGEWATER, N.J., Nov. 5, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Oct 30, 2025, 07:00 ET Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update
BRIDGEWATER, N.J., Oct. 30, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Oct 23, 2025, 16:05 ET Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List
BRIDGEWATER, N.J., Oct. 23, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Oct 17, 2025, 07:00 ET CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis
BRIDGEWATER, N.J., Oct. 17, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Oct 16, 2025, 07:00 ET Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025
BRIDGEWATER, N.J., Oct. 16, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Oct 15, 2025, 07:00 ET Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025
BRIDGEWATER, N.J., Oct. 15, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated
Sep 22, 2025, 07:00 ET Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025
N.J., Sept. 22, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
More news about: Insmed Incorporated